RecruitingPhase 2NCT05042102

Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder

Sponsor

VA Connecticut Healthcare System

Enrollment

160 participants

Start Date

Aug 8, 2022

Study Type

INTERVENTIONAL

Conditions

Alcohol Use Disorder

Summary

The goal of the project is to evaluate whether donepezil + cognitive remediation therapy is superior to placebo in reducing heavy drinking in patients with alcohol use disorder in a double-blind, placebo-controlled trial.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, and others for people with alcohol use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTDonepezil + Cognitive remediation therapy (CRT)

Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.

COMBINATION_PRODUCTDonepezil + Placebo CRT

Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.

COMBINATION_PRODUCTPlacebo medication + Cognitive remediation therapy (CRT)

Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.

COMBINATION_PRODUCTPlacebo medication + Placebo CRT

Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.